A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: pleasant (13), good (563), kind (168), polite (7), fine (98), lovely (4)

IRD(20)-Dexamethasone_20_Ixazomib-Lenalidomide

Description
Chemotherapy Protocol Myeloma IRD (20) - Dexamethasone (20)-Ixazomib-Lenalidomide Regimen • Myeloma – IRD (20) - Dexamethasone (20)-I
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IRD20-Dexamethasone-20-Ixazomib-Lenalidomide.pdf

Hospital trust to celebrate work of 'inspirational' volunteers

Description
Staff at Southampton's university hospitals are set to showcase the work of their 1,000-strong team of "inspirational" volunteers at
Url
/AboutTheTrust/Newsandpublications/Latestnews/2017/May-2017/Hospital-trust-to-celebrate-work-of-inspirational-volunteers.aspx

Papers CoG 29.04.2025 v2

Description
Date Time Location Chair Agenda Council of Governors 29/04/2025 14:00 - 15:45 Conference Room, Heartbeat/Microsoft Teams Jenni Douglas-Todd 1 Cha
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-29.04.2025-v2.pdf

Carboplatin Paclitaxel EC Pembrolizumab Neoadjuvant Ver1.0

Description
Chemotherapy Protocol BREAST CANCER PEMBROLIZUMAB WITH CARBOPLATIN/PACLITAXEL AND EC NEOADJUVANT BREAST CANCER FOLLOWED BY ADJUVANT PEMBROLIZUMAB Regime
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Carboplatin-Paclitaxel-EC-Pembrolizumab-Neoadjuvant.pdf

Glofitamab-Obinutuzumab

Description
Chemotherapy Protocol LYMPHOMA GLOFITAMAB-OBINUTUZUMAB Regimen • Lymphoma-Glofitamab-Obinutuzumab Indication • Treatment o
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Glofitamab-Obinutuzumab.pdf

Crizanlizumab Ver 1

Description
Chemotherapy Protocol Recurrent Vaso-Occlusive Crises in Sickle Cell Disease CRIZANLIZUMAB Regimen • Recurrent Vaso-Occlusive Crises in Sickle Cel
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sickle-Cell/Crizanlizumab-Ver-1.pdf

Papers Trust Board - 27 July 2023

Description
Date Time Location Chair Agenda Trust Board – Open Session 27/07/2023 9:00 - 13:15 Conference Room, Heartbeat/Microsoft Teams
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Papers-Trust-Board-27-July-2023.pdf

Azacitidine(SC)-Venetoclax

Description
Chemotherapy Protocol Acute Myeloid Leukaemia AZACITIDINE (SC) - VENETOCLAX Regimen  AML – Azacitidine (SC) - Venetoclax Indication  Newly diagnosed a
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/AzacitidineSC-Venetoclax.pdf

Routine pregnancy testing information for young people receiving systemic anti-cancer treatment (SACT) - patient information

Description
This factsheet contains information about routine pregnancy testing for young people receiving systemic anti-cancer treatment (SACT).
Url
/Media/UHS-website-2019/Patientinformation/Childhealth/Routine-pregnancy-testing-information-for-young-people-receiving-systemic-anti-cancer-treatment-SACT-3214-PIL.pdf

VR-RituximabVenetoclaxCycle_1_VenetoclaxDoseTitration

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) Cycle 1 – Venetoclax dose titration Regimen • CLL – VR Rituximab
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclaxCycle-1-VenetoclaxDoseTitration.pdf
81 to 90 of 245
Previous … 7 8 9 10 11 … Next